Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is well positioned for durable fundamental upside because its commercial anchor, VYJUVEK, is already proving that the company can translate its HSV-1 gene therapy platform into meaningful revenue and profitability, with 2025 revenue of $389M, gross profit of $366M, a 94% gross margin, and net income of $205M. Its outlook is further strengthened by ex-US expansion and a broad pipeline that includes KB801 in neurotrophic keratitis, KB803 in ocular DEB, KB407 in cystic fibrosis, and KB111 in Hailey-Hailey disease, giving it multiple shots on goal across large underserved rare-disease markets while management continues to benefit from strong capital efficiency and $1.0B in cash at the end of 1Q26. The stock also appears to have a favorable catalyst setup through 2H26, when registrational ophthalmology readouts for IOLITE and EMERALD-1, plus additional safety and interim data, could validate the platform beyond dermatology and expand the company from a single-product story into a multi-product, profitable biotech.

Krystal Biotech is a negative investment case because its current profitability is heavily concentrated in VYJUVEK, leaving the story dependent on a single commercial asset even as management itself points to only a modest annualized top-line of about $500m, while the pipeline still carries meaningful execution, regulatory, and safety risk. Although the company reports industry-leading gross margins of about 95%, in-house manufacturing, and positive cash flow, the same excerpts highlight unresolved concerns around HSV-1 vector safety, skepticism on KB801, KB407, and KB408, and the possibility that disappointing efficacy could force pricing pressure, limiting how far the platform can scale beyond the base business. Even with $1B in cash as of 1Q26 and multiple late-stage readouts expected in 2026, the absence of proven diversification and the need to validate several programs in the face of clinical and competitive uncertainty make the downside profile more attractive than the long-term upside.